Notice of Intent to Sole Source - EzPlaz

The Defense Health Agency (DHA) intends to award an indefinite‑delivery/indefinite‑quantity (IDIQ) firm‑fixed‑price contract on a sole‑source basis for FDA‑approved freeze‑dried plasma (EZPLAZ™). Only Vascular Solutions LLC holds the exclusive FDA‑approved product, and the DHA seeks capability statements from interested parties that can demonstrate the ability to provide the product. Submissions must be concise, no more than five pages, and are due by September 16, 2026. The contract will be awarded without further competition if no responses are received. • Sole‑source IDIQ for FDA‑approved freeze‑dried plasma (EZPLAZ™). • Capability statements limited to five 8.5×11” pages, submitted via email. • Deadline: 3 PM EDT, 16 Sep 2026; award will occur after review of submissions.